PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)

Published:2017-03-01 Issue:16 Volume:8 Page:26845-26857
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Jiang Liyan¹,Su Xinying²,Zhang Tianwei²,Yin Xiaolu²,Zhang Meizhuo³,Fu Haihua²,Han Hulin²,Sun Yun²,Dong Lili¹,Qian Jialin¹,Xu Yanhua⁴,Fu Xuan⁴,Gavine Paul R.²,Zhou Yanbin⁵,Tian Kun⁶,Huang Jiaqi⁷,Shen Dong⁷,Jiang Haiyi⁴,Yao Yihong⁷,Han Baohui¹,Gu Yi²

Affiliation:

1. Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

2. Asia & Emerging Markets, iMed, AstraZeneca, Shanghai, China

3. R&D Information, AstraZeneca, Shanghai, China

4. Global Medicines Development, AstraZeneca, Shanghai, China

5. The First Affiliated Hospital, Sun Yat-Sen University, Guangdong, China

6. General Hospital of Chengdu Military Region of PLA, Sichuan, China

7. R&D, MedImmune, AstraZeneca, Gaithersburg, MD, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation between PD-L1 expression status and efficacy of immunotherapy as second-line or later-line therapy in advanced non-small cell lung cancer patients;European Journal of Cancer Prevention;2024-02-23

2. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer;Medicine;2024-02-23

3. Serum ferritin level is an effective prognostic factor for lung cancer immunotherapy;Cancer Biology & Therapy;2023-11-30

4. Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma;Anticancer Research;2023-11

5. Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer;International Journal of Molecular Sciences;2023-07-15